Methodological quality was critically low in 9/10 systematic reviews in advanced cancer patients-A methodological study
Copyright © 2021 Elsevier Inc. All rights reserved..
OBJECTIVE: To assess the methodological quality and the consideration of heterogeneity in systematic reviews (SRs).
STUDY DESIGN AND SETTING: We conducted a methodological study (CRD42019134904) and searched three databases from January 2010 to July 2019. Interventional SRs with a statistically significant meta-analysis of at least four randomized controlled trials in advanced cancer patients were included. A MeaSurement Tool to Assess Systematic Reviews (AMSTAR) 2 was used to evaluate the SRs' methodological quality. The consideration of heterogeneity was categorized in clinical or/and methodological heterogeneity and not explored.
RESULTS: From 6234 identified references, 261 SRs were included. Most SRs had a critically low quality (230, 88.1%). The majority of them (209, 80.1%) was classified as critically low because of non-registration (222, 85.1%) combined with the non-reporting of excluded full-texts and missing justifications for exclusion (218, 83.5%). Heterogeneity in trial results was not explored at all in 51 (19.5%) SRs whereas clinical heterogeneity was considered in 117 (44.8%), methodological heterogeneity in 13 (5.0%), and both clinical and methodological heterogeneity in 80 (30.7%) SRs.
CONCLUSION: The consideration of these findings in trainings for review authors and peer reviewers could improve the awareness of quality criteria and the quality of future SRs.
TRIAL REGISTRATION: PROSPERO-ID: CRD42019134904.
| Errataetall: |
CommentIn: J Clin Epidemiol. 2021 Oct;138:234. - PMID 34077796 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:136 |
|---|---|
| Enthalten in: |
Journal of clinical epidemiology - 136(2021) vom: 30. Aug., Seite 84-95 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siemens, Waldemar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AMSTAR 2 |
|---|
| Anmerkungen: |
Date Completed 15.10.2021 Date Revised 18.11.2021 published: Print-Electronic CommentIn: J Clin Epidemiol. 2021 Oct;138:234. - PMID 34077796 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jclinepi.2021.03.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32297951X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32297951X | ||
| 003 | DE-627 | ||
| 005 | 20231225183202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jclinepi.2021.03.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM32297951X | ||
| 035 | |a (NLM)33741503 | ||
| 035 | |a (PII)S0895-4356(21)00082-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Siemens, Waldemar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methodological quality was critically low in 9/10 systematic reviews in advanced cancer patients-A methodological study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2021 | ||
| 500 | |a Date Revised 18.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Clin Epidemiol. 2021 Oct;138:234. - PMID 34077796 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To assess the methodological quality and the consideration of heterogeneity in systematic reviews (SRs) | ||
| 520 | |a STUDY DESIGN AND SETTING: We conducted a methodological study (CRD42019134904) and searched three databases from January 2010 to July 2019. Interventional SRs with a statistically significant meta-analysis of at least four randomized controlled trials in advanced cancer patients were included. A MeaSurement Tool to Assess Systematic Reviews (AMSTAR) 2 was used to evaluate the SRs' methodological quality. The consideration of heterogeneity was categorized in clinical or/and methodological heterogeneity and not explored | ||
| 520 | |a RESULTS: From 6234 identified references, 261 SRs were included. Most SRs had a critically low quality (230, 88.1%). The majority of them (209, 80.1%) was classified as critically low because of non-registration (222, 85.1%) combined with the non-reporting of excluded full-texts and missing justifications for exclusion (218, 83.5%). Heterogeneity in trial results was not explored at all in 51 (19.5%) SRs whereas clinical heterogeneity was considered in 117 (44.8%), methodological heterogeneity in 13 (5.0%), and both clinical and methodological heterogeneity in 80 (30.7%) SRs | ||
| 520 | |a CONCLUSION: The consideration of these findings in trainings for review authors and peer reviewers could improve the awareness of quality criteria and the quality of future SRs | ||
| 520 | |a TRIAL REGISTRATION: PROSPERO-ID: CRD42019134904 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AMSTAR 2 | |
| 650 | 4 | |a Heterogeneity | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Methodological quality | |
| 650 | 4 | |a Neoplasms | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Schwarzer, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Rohe, Miriam S |e verfasserin |4 aut | |
| 700 | 1 | |a Buroh, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Meerpohl, Jörg J |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Gerhild |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical epidemiology |d 1991 |g 136(2021) vom: 30. Aug., Seite 84-95 |w (DE-627)NLM012614815 |x 1878-5921 |7 nnns |
| 773 | 1 | 8 | |g volume:136 |g year:2021 |g day:30 |g month:08 |g pages:84-95 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jclinepi.2021.03.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 136 |j 2021 |b 30 |c 08 |h 84-95 | ||